Evidence map›Paper›PMID 41304968›Full record

ArticlePharmaceuticals (Basel, Switzerland)2025

New Anti-Cancer Impact of Cerium Oxide, Lithium, and Sn-38 Synergy via DNA Methylation-Mediated Reduction of MMP-2 and Modulation of the PI3K/Akt/mTOR Pathway.

Sidika Genc, Hayrunnisa Nadaroglu, Ramazan Cinar, Esmanur Nigde, Kubra Karabulut, Ali Taghizadehghalehjoughi

Abstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Sidika GencDepartment of Medical Pharmacology, Faculty of Medicine, Bilecik Şeyh Edebali University, 11230 Bilecik, Turkey.ORCID 0000-0003-0000-5103
Hayrunnisa NadarogluDepartment of Food Technology, Vocational College of Technical Science, Ataturk University, 25240 Erzurum, Turkey.ORCID 0000-0002-0536-4212
Ramazan CinarDepartment of Biophysics, Faculty of Medicine, Bilecik Şeyh Edebali University, 11230 Bilecik, Turkey.ORCID 0000-0003-3637-7849
Esmanur NigdeDepartment of Medical Pharmacology, Faculty of Medicine, Bilecik Şeyh Edebali University, 11230 Bilecik, Turkey.ORCID 0009-0004-6007-472X
Kubra KarabulutDepartment of Medical Pharmacology, Faculty of Medicine, Bilecik Şeyh Edebali University, 11230 Bilecik, Turkey.ORCID 0009-0002-7052-6086
Ali TaghizadehghalehjoughiDepartment of Medical Pharmacology, Faculty of Medicine, Bilecik Şeyh Edebali University, 11230 Bilecik, Turkey.ORCID 0000-0002-3506-0324

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

anti-cancercerium oxideglioblastomalithiumSN-38

Identifiers

PMID41304968
PMCPMC12655311

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.